# Pamela Walker

> Pamela Walker is a seed investor at THENA Capital backing Health Care. See 3 investments, check sizes, portfolio and contact details. Updated Oct 2026.

- Type: Angel Investor
- Fund: [THENA Capital](https://shizune.co/investors/profile/thena-capital)
- Location: London, United Kingdom
- Total investments: 3
- Last investment: May 2026
- Lead investor: 67%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/in/drpamelawalker-medtech-lifescience-expert

Pamela Walker is a seed investor at THENA Capital in London focused on Health Care and Fitness. Pamela Walker is the founder of Thena Capital.

## Contacts

5 contacts available for Pamela Walker: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/pamela-walker-352e?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 67% |
| Fitness | 1 | 33% |
| Wellness | 1 | 33% |
| Biotechnology | 1 | 33% |
| Personal Health | 1 | 33% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 67% |
| Pre-Seed | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Zonova | Zonova has developed an antimicrobial additive technology that integrates directly into the polymers used in medical device manufacture, designed to help prevent healthcare-associated infections, a problem affecting roughly 1 in 10 hospital patients worldwide (WHO, 2011). Our patented Z-ROS® chemistry is a non-leaching antimicrobial additive basedon reactive-oxygen-species generation at the polymer surface. It does not use actives, antibiotics or biocides.Z-ROS® is in development for high infection-risk device categories including vascular access devices, orthopaedic implants, urology (connectors, valves, catheters), endotracheal tubes, and pelvic health devices. The intended commercial model is licensing to medical device manufacturers, with masterbatch supply through a contracted compounder. | $2.8M | Seed | May 26, 2026 | https://zonovatech.com |
| Salient Bio | Salient Bio is building non-invasive diagnostic tests that address difficult-to-identify medical conditions, such as Crohn’s Disease and Ulcerative Colitis. For this we use a combination of microbiome metagenomics and machine learning, which we couple with classical diagnostic approaches. We currently focus on testing human gut, oral, and vaginalmicrobiomes, for which we have built comprehensive bioinformatic analysis options. Our ISO17025-certified lab portfolio also includes a range of classical blood and stool diagnostic tests which we offer alongside our microbiome testing service for our revenue generating proposition. | $3.2M | Seed | Sep 03, 2025 | https://salient.bio |
| Samphire Neuroscience | Samphire Neuroscience builds clinically validated neurotechnology to support women across their lives. Our wearable devices, Nettle™ and Lutea™, are built on the same underlying brain-stimulation technology, targeting neural pathways involved in pain, mood, stress, and sleep regulation. - Lutea™ is available globally as a wellness device. Itstimulates the same regions of the brain to support stress regulation, sleep, and recovery - key drivers of readiness and long-term performance - allowing athletes and teams to move beyond wellbeing education alone to practical, evidence-based intervention. - Nettle™ is a CE-marked (EU and UK regulated), drug- and hormone-free device that has been clinically shown to improve pain, mood, functionality, and the ability to train during the menstrual cycle, with measurable benefits after one month of use - supporting athletes to maintain training intensity and movement quality during their period. - The Samphire App is the platform controlling all Samphire hardware products with the use of CycleSync™ AI technology: the only one of its kind to support personalized neurotechnology use for women. | $2.3M | Pre-Seed | Feb 21, 2024 | https://www.samphireneuro.com |

3 of 3 investments shown.

## Co-investors
- [Seaside Ventures](https://shizune.co/investors/profile/seaside-ventures) — VC Fund, 2 deals together
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund, 2 deals together
- [AfterWork Ventures](https://shizune.co/investors/profile/afterwork-ventures) — VC Fund, 1 deal together
- [Alberts Impact Ventures](https://shizune.co/investors/profile/alberts-impact-capital) — VC Fund, 1 deal together
- [Angel Academe](https://shizune.co/investors/profile/angel-academe) — VC Fund, 1 deal together
- [Animal Health Angels](https://shizune.co/investors/profile/animal-health-angels) — VC Fund, 1 deal together

## About THENA Capital

VC Fund · London, United Kingdom

THENA Capital is a venture capital firm investing in early-stage MedTech startups with a focus on women's health and digital care.

3 contacts available at THENA Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Jason Foster | Venture Partner | https://shizune.co/investors/profile/jason-c-foster |
| Pamela Walker | Founding General Partner | https://shizune.co/investors/profile/pamela-walker-352e |
| Tatum Getty | Founding General Partner | https://shizune.co/investors/profile/tatum-getty |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund

## FAQ

### What does Pamela Walker invest in?

Pamela Walker invests primarily in Health Care, Fitness and Wellness startups, most often at Seed and Pre-Seed stage. Most of the 3 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Pamela Walker?

Public channels for Pamela Walker include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Pamela Walker last invest?

The most recent investment recorded for Pamela Walker closed in May 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co